Multiple Sclerosis Therapeutic Market To Reach $38.62 Billion By 2030

June 2025 | Report Format: Electronic (PDF)

Multiple Sclerosis Therapeutic Market Growth & Trends

The global multiple sclerosis therapeutic market size is estimated to reach USD 38.62 billion by 2030, registering a CAGR of 5.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of high unmet clinical needs in developing regions is one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in spreading awareness among people regarding progressive multiple sclerosis and the symptoms associated with it. Some notable examples include the National Multiple Sclerosis Society (NMSS) in the U.S., Multiple Sclerosis International Federation in Canada, European Multiple Sclerosis Platform (EMSP), and the Multiple Sclerosis Society (MSC).

Reimbursement programs are also anticipated to enhance the penetration of multiple sclerosis drugs. For instance, In June 2014, Biogen Idec Canada, announced that its TECFIDERA drug for the treatment of MS is available for reimbursement in British Colombia through B.C PharmaCare.

The introduction of novel therapeutics with minimal dosage requirement and cost-effectiveness is further expected to favor market growth. For, instance Lemtrada by Sanofi needs to be administered 3-5 times per year as compared to Copaxone, which requires daily administration.

key Request a free sample copy or view report summary: Multiple Sclerosis Therapeutic Market Report

Multiple Sclerosis Therapeutic Market Report Highlights

Based on drug class, the immunosuppressant segment dominated the market with the largest revenue share of 60.50% in 2024. The presence of a strong drug pipeline and its expected commercialization in the coming six years are some factors expected to drive market growth.
Based on route of administration, the oral segment is expected to grow at the fastest CAGR rate over the forecast period, propelled by increasing patient preference for convenient, home-based treatment options.
In 2024, the injectable market held the largest share of 52.50% in 2024, owing to high prescription rates & price.
North America dominated the global market with a share of 38.28% in 2024. The increasing prevalence of multiple sclerosis, the introduction of new drugs, and high prices of drugs, such as Tysabri and Aubagio in the U.S., are some factors responsible for its dominance.

Multiple Sclerosis Therapeutic Market Segmentation

Grand View Research has segmented the global multiple sclerosis therapeutic market based on drug class, route of administration, distribution channel, and region:

Multiple Sclerosis Drug Class Outlook (Revenue, USD Million, 2018 - 2030)